7,903 results match your criteria Cerebral Venous Thrombosis

Early and late-onset nonconvulsive status epilepticus after stroke.

Arq Neuropsiquiatr 2021 May;79(5):384-389

Antalya Education and Research Hospital, Department of Neurology, Antalya, Turkey.

Background: Nonconvulsive status epilepticus (NCSE) is a condition that needs timely diagnosis and treatment. It has insignificant clinical features and presents high risk of misdiagnosis.

Objective: To investigate NCSE among patients with stroke, given that stroke plays an important role in the etiology of NCSE. Read More

View Article and Full-Text PDF

Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations.

Br J Haematol 2021 Jun 22. Epub 2021 Jun 22.

National Coagulation Centre, St. James's Hospital, Dublin, Ireland.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a novel entity that emerged in March 2021 following reports of unusual thrombosis after ChAdOx1 nCoV-19, (AstraZeneca) vaccination. Following the recognition of this syndrome, multiple consensus guidelines have been released to risk stratify patients presenting with possible symptoms after ChAdOx1 nCoV-19 vaccination. All guidelines rapidly identify VITT in patients with the complete triad of thrombocytopenia, thrombosis and elevated D-dimers after ChAdOx1 nCoV-19 vaccination. Read More

View Article and Full-Text PDF

[Incidence and risk factors of venous thromboembolic events after resection of various brain tumors].

Zh Vopr Neirokhir Im N N Burdenko 2021 ;85(3):63-75

FSBI «Federal Center for Neurosurgery» of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.

Venous thromboembolic events (VTE) can significantly complicate postoperative period in neurosurgical patients. It is known that patients with brain tumors are especially susceptible to VTE.

Objective: To determine the incidence and risk factors of VTE in patients with various brain tumors. Read More

View Article and Full-Text PDF

Endovascular Intervention for Refractory Pediatric Cerebral Venous Sinus Thrombosis.

Pediatr Neurol 2021 May 11;121:45-50. Epub 2021 May 11.

Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas. Electronic address:

Background: Cerebral venous sinus thrombosis (CVST) is a rare but potentially morbid disease in the pediatric population, and the optimal treatment is not fully understood. Endovascular intervention for this condition has been rarely reported.

Methods: The Stroke Thrombectomy and Aneurysm Registry was queried for patients aged less than or equal to 18 years undergoing endovascular treatment for CVST in the past 10 years. Read More

View Article and Full-Text PDF

[Guidelines on: COVID-19 Vaccine Induced Thrombosis, Bleeding, and Thrombocytopenia].

Acta Med Port 2021 Jun 18. Epub 2021 Jun 18.

Unidade de Trombose e Hemostase. Serviço de Hematologia Clínica. Hospital de Santo António. Centro Hospitalar Universitário do Porto. Porto. Basic and Clinical Research on Iron Biology Group. Instituto de Investigação e Inovação em Saúde - i3S. Universidade do Porto. Porto. Portugal.

After widespread vaccination with COVID-19 vaccines, there have been worldwide reports on thrombosis, bleeding, and thrombocytopenia. Recently, a rare syndrome with a high mortality rate consisting of an unusual combination of thrombocytopenia and thrombosis, in particular cerebral venous sinus thrombosis, which clinically resembles heparin-induced thrombocytopenia, was reported following vaccination. Different statements and recommendations were developed regarding the definition, diagnosis, and treatment of these rare complications. Read More

View Article and Full-Text PDF

Artery and venous sinus occlusion image score (AVOIS): A novel method to evaluate occlusive cerebral arteries and venous diseases.

CNS Neurosci Ther 2021 Jun 19. Epub 2021 Jun 19.

Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Aim: To establish an artery and venous sinus occlusion image score (AVOIS) which is compatible in both cerebral arteries and venous system diseases.

Methods: A total of 188 consecutive patients with the final diagnosis of anterior circulation infarct (ACI) and 56 consecutive patients with cerebral venous and sinus thrombosis (CVST) were retrospectively studied. The AVOIS was developed based on the severity of occlusive changes of main intracranial arteries and venous sinuses (present = 0, partial occlusion = 1, absent = 2), and divided into four groups (CVST group: 0, 1-5, 6-10, >10. Read More

View Article and Full-Text PDF

A study of hyperhomocysteinemia in cerebral venous sinus thrombosis.

Indian J Med Res 2020 Dec;152(6):584-594

Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

Background & Objectives: Vegetarianism may result in low vitamin B12 and acquired hyperhomocysteinemia leading to thrombotic conditions such as cerebral venous sinus thrombosis (CVST). The clinico-radiological presentation and outcome of patients with hyperhomocysteinemia may be different from those without, but there is a paucity of information. This study was undertaken to find out the relationship of homocysteine (Hcy) with vitamin B12, folic acid and methyltetrahydrofolate reductase (MTHFR) mutation in the patients with CVST, and compare clinico-radiological severity and outcome of patients with and without hyperhomocysteinemia. Read More

View Article and Full-Text PDF
December 2020

Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia.

Thromb Res 2021 Jun 9;204:40-51. Epub 2021 Jun 9.

From Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.

Heparin-induced thrombocytopenia (HIT) is characterized clinically by thrombocytopenia, hypercoagulability, and increased thrombosis risk, and serologically by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies. Heparin-"induced" acknowledges that HIT is usually triggered by a proximate immunizing exposure to heparin. However, certain non-heparin medications (pentosan polysulfate, hypersulfated chondroitin sulfate, fondaparinux) can trigger "HIT". Read More

View Article and Full-Text PDF

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines.

J Autoimmun 2021 Jun 14;122:102681. Epub 2021 Jun 14.

The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK.

Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV. Read More

View Article and Full-Text PDF

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2.

Blood Adv 2021 Jun;5(12):2569-2574

Section of Transfusion Medicine, Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Recently, reports of severe thromboses, thrombocytopenia, and hemorrhage in persons vaccinated with the chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19, AZD1222, Vaxzevria; Oxford/AstraZeneca) against severe acute respiratory syndrome coronavirus 2 have emerged. We describe an otherwise healthy 30-year-old woman who developed thrombocytopenia, ecchymosis, portal vein thrombosis, and cerebral venous sinus thrombosis the second week after she received the ChAdOx1 nCoV-19 vaccine. Extensive diagnostic workup for thrombosis predispositions showed heterozygosity for the prothrombin mutation, but no evidence of myeloproliferative neoplasia or infectious or autoimmune diseases. Read More

View Article and Full-Text PDF

Case Study of Pediatric Cerebral Sinus Venous Thrombosis Center of a Low Middle-Income Country.

Clin Appl Thromb Hemost 2021 Jan-Dec;27:10760296211022847

Department of Oncology, Aga Khan University, Karachi, Pakistan.

Pediatric cerebral venous sinus thrombosis (CVST) is rare but a potentially fatal disease requiring its understanding in local setting. In this study, we observed the clinical course, management, and outcome of pediatric patients with sinus thrombosis in a tertiary care center at Pakistan. Patients between age 0 to 18 years of both genders diagnosed with sinus thrombosis during 2011 to 2020 were included. Read More

View Article and Full-Text PDF

Clinical observations in patients with cerebral venous sinus thrombosis.

Br J Haematol 2021 Jun 16. Epub 2021 Jun 16.

Department of Haematology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.

View Article and Full-Text PDF

ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST).

BMJ Case Rep 2021 Jun 16;14(6). Epub 2021 Jun 16.

Cardiology, West Suffolk Hospitals NHS Trust, Bury Saint Edmunds, Suffolk, UK.

A 27-year-old fit and well man presented with intermittent headaches associated with eye floaters and vomiting. His symptoms started 48 hours after having the first dose of ChADOx1 nCOV-19 vaccine (Vaxzevria, previously AstraZeneca COVID-19 vaccine; AstraZeneca) and bloods showed raised D-dimer, low platelets and fibrinogen. CT venogram demonstrated significant cerebral venous sinus thrombosis. Read More

View Article and Full-Text PDF

Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.

BMC Neurol 2021 Jun 16;21(1):225. Epub 2021 Jun 16.

Department of Neurology, Aerospace Center Hospital, Beijing, China.

Background: Cerebral venous thrombosis (CVT) occurs rarely in the general population and is frequently associated with confused clinical findings and delayed diagnosis. Isolated cerebellar cortical vein thrombosis is a very rare phenomenon.

Case Presentation: This report describes a case with CVT, which is manifested as space-occupying lesions of the cerebellar hemisphere and mimics a cerebellar tumor at the beginning. Read More

View Article and Full-Text PDF

Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions.

J Neurol Sci 2021 Jun 5;427:117532. Epub 2021 Jun 5.

Department of Neurology, Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, NY, USA.

Background: Vaccine induced immune mediated thrombocytopenia or VITT, is a recent and rare phenomenon of thrombosis with thrombocytopenia, frequently including cerebral venous thromboses (CVT), that has been described following vaccination with adenovirus vaccines ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2·S Johnson and Johnson (Janssen/J&J). The evaluation and management of suspected cases of CVT post COVID-19 vaccination are critical skills for a broad range of healthcare providers. Read More

View Article and Full-Text PDF

Superior sagittal sinus thrombosis masquerading as intracerebral and subdural haemorrhage.

J R Coll Physicians Edinb 2021 06;51(2):164-165

Medical Unit, Dumfries Royal Infirmary, Dumfries, UK.

View Article and Full-Text PDF

Isolated cortical vein thrombosis in a young male adult.

BMJ Case Rep 2021 Jun 15;14(6). Epub 2021 Jun 15.

Department of Medicine, Montefiore New Rochelle Hospital, New Rochelle, New York, USA.

Isolated cortical vein thrombosis (ICVT) is a rare entity and accounts for only 6.3% of cerebral venous and sinus thrombosis. ICVT is an uncommon cause of seizures in young adults. Read More

View Article and Full-Text PDF

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis.

J Thromb Thrombolysis 2021 Jun 15. Epub 2021 Jun 15.

Division of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, 1 Place de l'Hôpital, 67000, Strasbourg, France.

View Article and Full-Text PDF

[Bacterial Meningitis and Suppurative Thrombophlebitis after Trigger Point Injections: A Case Report].

Brain Nerve 2021 Jun;73(6):737-740

Department of Neurology, Kobe City Medical Center General Hospital.

A 73-year-old woman with untreated diabetes mellitus visited our emergency department with a 4-day history of progressive headache, fever, and chills. She received trigger point injections (TPI) into the right sternocleidomastoid for exercise-induced ipsilateral shoulder pain, 13 days before admission and into the right trapezius, 6 days before admission. Cerebrospinal fluid (CSF) evaluation revealed pleocytosis with a predominance of neutrophils, as well as elevated protein and reduced glucose levels. Read More

View Article and Full-Text PDF

Clinical Profile and Long-Term Outcome in Neonatal Cerebral Sinus Venous Thrombosis.

Pediatr Neurol 2021 May 15;121:20-25. Epub 2021 May 15.

Department of Pediatrics, Section of Pediatric Neurology and Developmental Neuroscience, Baylor College of Medicine, Houston, Texas. Electronic address:

Background: Neonatal cerebral sinus venous thrombosis (CSVT) causes high morbidity and mortality. Factors associated with either favorable or unfavorable long-term outcomes have not been clearly established. This study aimed to determine the factors involved in long-term neurological outcomes in patients with neonatal CSVT. Read More

View Article and Full-Text PDF

Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.

Curr Neurol Neurosci Rep 2021 Jun 14;21(8):41. Epub 2021 Jun 14.

Neurology, Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal.

Purpose Of Review: In recent years, the spectrum of neurological manifestations of antiphospholipid syndrome (APS) has been growing. We provide a critical review of the literature with special emphasis on presentation, proposed mechanisms of disease, and treatment of neurological involvement in APS.

Recent Findings: Although stroke is the most common cause of neurological manifestations in patients with APS, other neurological disorders have been increasingly associated with the disease, including cognitive dysfunction, headache, and epilepsy. Read More

View Article and Full-Text PDF

Oral tranexamic acid and thrombosis risk in women.

EClinicalMedicine 2021 May 6;35:100882. Epub 2021 May 6.

Department of Gynaecology, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Background: Oral tranexamic acid is effective for heavy menstrual bleeding, but the thrombosis risk with this treatment is largely not studied.

Methods: Using nationwide registries, we assessed associations between use of oral tranexamic acid and risk of deep-vein thrombosis or pulmonary embolism and arterial thrombosis in heart or brain in a nationwide historical prospective cohort of Danish women aged 15 to 49 years in the period 1996-2017. Exclusion criteria included potential confounding factors such as history of thromboembolism, anticoagulation therapy, thrombophilia, and cancer. Read More

View Article and Full-Text PDF

Impact of anticoagulation status on recanalization and outcome of cerebral venous thrombosis.

J Clin Neurosci 2021 Jul 29;89:43-50. Epub 2021 Apr 29.

Apollo Medics Super-specialty Hospitals and Senior consultant neurologist, Vivekanand Polyclinic, and Institute of Medical science, Lucknow 226001, India.

Effective anticoagulation status may determine the recanalization and outcome of cerebral venous thrombosis (CVT). We report impact of anticoagulation status on recanalization and outcome of CVT. This is a retrospective study on 126 patients with CVT diagnosed on magnetic resonance venography (MRV). Read More

View Article and Full-Text PDF

Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination.


Neurologia (Engl Ed) 2021 May 29. Epub 2021 May 29.

Introduction: Cases of cerebral venous sinus thrombosis have been reported in individuals vaccinated against COVID-19 with non-replicating adenoviral vector vaccines. We issue our recommendations on the diagnosis and management of patients presenting this complication.

Methods: The multidisciplinary working group, led by the Spanish Federation of Medical and Scientific Associations (FACME) and including representatives of several scientific societies, reviewed the available evidence from the literature and reports of the European Medicines Agency. Read More

View Article and Full-Text PDF

Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine.

J Stroke Cerebrovasc Dis 2021 May 25;30(8):105906. Epub 2021 May 25.

Department of Neurology, Centro Hospitalar Universitário de São João, E.P.E., Porto, Portugal; Clinical Neurosciences and Mental Health Department, Faculty of Medicine of the University of Porto, Portugal.

The development of SARS-CoV-2 vaccines has raised several concerns regarding venous thromboembolism, namely cerebral venous thrombosis. Although cerebral venous thrombosis has been reported after administration of a viral vector vaccine, due to a possible auto-immune mechanism inducing thrombocytopenia, the same has not happened in mRNA vaccines. We report two cases of cerebral venous thrombosis, shortly after administration of mRNA vaccine. Read More

View Article and Full-Text PDF

Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine. A case report.

J Crit Care 2021 Jun 4;65:72-75. Epub 2021 Jun 4.

SC Anestesia e Rianimazione II, Ospedale San Carlo Borromeo, ASST Santi Paolo e Carlo - Polo Universitario, Milano, Italy.

Several cases of deep venous thrombosis in people who had recently received Vaxzevria (previously known as COVID-19 Vaccine AstraZeneca) have recently been reported, mainly presenting as cerebral vein/cerebral venous sinus thrombosis. This syndrome has been termed "vaccine-induced immune thrombotic thrombocytopenia (VITT)". Acute spleno-porto-mesenteric vein thrombosis is an uncommon but serious condition with potential sequelae, such as small-bowel gangrene and end-stage liver failure. Read More

View Article and Full-Text PDF

Current management of cancer-associated venous thromboembolism in patients with thrombocytopenia: a retrospective cohort study.

Intern Emerg Med 2021 Jun 10. Epub 2021 Jun 10.

Thrombosis and Hemorragic Diseases Unit, IRCCS Humanitas Clinical and Research Hospital, Milan, Italy.

Optimal management of venous thromboembolism (VTE) in cancer patients with thrombocytopenia is uncertain. We described current management and clinical outcomes of these patients. We retrospectively included a cohort of cancer patients with acute VTE and concomitant mild (platelet count 100,000-150,000/mm), moderate (50,000-99,000/mm), or severe thrombocytopenia (< 50,000/mm). Read More

View Article and Full-Text PDF

The Role of Thrombo-Inflammatory Biomarkers in the Prognosis of Cerebral Venous Sinus Thrombosis.

Curr Neurovasc Res 2021 Jun 7. Epub 2021 Jun 7.

Karadeniz Technical University, Faculty of Medicine, Department of Neurology, Trabzon, Turkey.

Background: The role of inflammation in the prognosis of cerebral venous sinus thrombosis (CVST) has been demonstrated in a small number of studies. The platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and the systemic immune-inflammatory index (SII) have been studied as prognostic inflammatory biomarkers in numerous thrombo-embolic diseases. However, the number of studies evaluating the relationship between these parameters and CVST is very low. Read More

View Article and Full-Text PDF

Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia.

N Engl J Med 2021 Jun 9. Epub 2021 Jun 9.

From the Departments of Medicine (A.B., D.M.A., T.E.W., J.W.S., Z.A.A.A.M., A.S., J.G.K., I.N.) and Pathology and Molecular Medicine (A.B., T.E.W.), Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, the Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB (T.P., J.M.S.), the Department of Hematology/Oncology, Centre Hospitalier de l'Université de Montreal, Montreal (N.B.), and the Department of Hematology/Oncology, Hôpital Régional de Saint-Jérôme, St. Jerome, QC (M.-C.L.) - all in Canada.

The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against coronavirus disease 2019 (Covid-19). We describe the response to IVIG therapy in three of the first patients in whom VITT was identified in Canada after the receipt of the ChAdOx1 nCoV-19 vaccine. The patients were between the ages of 63 and 72 years; one was female. Read More

View Article and Full-Text PDF